HC Wainwright Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $10.00 price target on the stock.

Separately, Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Friday, March 22nd.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX traded up $0.04 during trading on Tuesday, reaching $1.60. The company had a trading volume of 258,868 shares, compared to its average volume of 437,802. Compass Therapeutics has a 52 week low of $1.15 and a 52 week high of $3.62. The stock has a market cap of $220.14 million, a PE ratio of -4.66 and a beta of 0.92. The business’s 50 day moving average price is $1.78 and its 200-day moving average price is $1.68.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Equities analysts anticipate that Compass Therapeutics will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. increased its position in shares of Compass Therapeutics by 2.1% during the third quarter. Adage Capital Partners GP L.L.C. now owns 6,380,000 shares of the company’s stock valued at $12,569,000 after buying an additional 130,000 shares during the period. Blackstone Inc. grew its holdings in shares of Compass Therapeutics by 3.1% during the third quarter. Blackstone Inc. now owns 6,189,551 shares of the company’s stock worth $12,193,000 after purchasing an additional 188,811 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after purchasing an additional 71,008 shares in the last quarter. CM Management LLC grew its holdings in shares of Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock worth $614,000 after purchasing an additional 185,000 shares in the last quarter. Finally, Element Capital Management LLC purchased a new position in shares of Compass Therapeutics during the fourth quarter worth about $458,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.